Hematolojik Malignitelerde Kemoterapi Protokolleri

1-Andersson, B. S., P. F. Thall, B. C. Valdez, et al. 2017. "Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients." Bone Marrow Transplant 52(4):580-587.

2-Bashir, Q., P. F. Thall, D. R. Milton, et al. 2019. "Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial." Lancet Haematol 6(5):e266-e275.

3-Blanes, M., J. D. Gonzalez, J. J. Lahuerta, et al. 2015. "Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma." Leuk Lymphoma 56(2):415-419.

4-Blanes, M., J. J. Lahuerta, J. D. Gonzalez, et al. 2013. "Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach." Biol Blood Marrow Transplant 19(1):69-74.

5-Jung, S. H., J. J. Lee, J. S. Kim, et al. 2018. "Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)." Biol Blood Marrow Transplant 24(5):923-929.

6-Kebriaei, P., T. Madden, R. Kazerooni, et al. 2011. "Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies." Biol Blood Marrow Transplant 17(3):412-420.

7-Grigg, A. P., J. Stone, A. D. Milner, et al. 2010. "Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma." Leuk Lymphoma 51(4):641-649.

8-Palmer, J., J. S. McCune, M. A. Perales, et al. 2016. "Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee." Biol Blood Marrow Transplant 22(11):1915-1925.

9-Andersson, B. S., M. de Lima, P. F. Thall, et al. 2008. "Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS." Biol Blood Marrow Transplant 14(6):672-684.

10-Ritchie, D. S., J. F. Seymour, A. P. Grigg, et al. 2007. "The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma." Ann Hematol 86(2):101-105.

11-Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE. Reduced-Toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukaemia.2009 Curr Opin Oncol. ; 21(Suppl.1) S11-S15.

12-Ria R, Falzetti F, Ballanti S, Minelli O, Di Ianni M, Cimminiello M, et al.Melphalan versus melphalan plus Busulfan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J. 2004; 5(2): 118-22.

13-Lemoli RM, D'Addio A, Marotta G, Pezzullo L, Zuffa E, Montanari M, et al.A.BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. Bone Marrow Transplant. 2010; 45(4): 640-6